Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corindus Vascular Robotics Inc.

Division of Siemens Healthineers AG
www.corindus.com

Latest From Corindus Vascular Robotics Inc.

Market Brief: Robotic Surgery Systems Market Will Reach $9.7Bn By 2023; Driven By Innovation, Procedure Volume Growth And Access To Emerging Markets

The global market for robotic surgery systems is expected to grow at a CAGR of 16%, reaching $9.7bn by 2023, driven by continued innovation, access to emerging markets and rising demand. 

Market Intelligence Robotics

Siemens Healthineers In Line With Future Trends As It Mines Workflow And Outcomes Seams

Siemens Healthineers  ̶  an engineering company by background – sees itself well positioned to benefit from the markets’ movement towards digital, workflows, robotics and minimally-invasive procedures. As such, it has advantages over pharma companies in being able to deliver better patient outcomes at lower cost and more effectively.

Commercial Medical Device

Corindus Envisions Network Of CorPath Robots For Remote Neurovascular And Coronary Interventions

The physician who led the first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.

Innovation Clinical Trials

Global Device Approvals Q2 Shapshot: Coronary Devices Abound

The second quarter of 2018 brought 62 approvals from outside the US, including 46 in Europe, according to Medtech Insight's Approvals Tracker. Among those approvals, 14 were for devices to treat coronary artery disease, and the second most-common indications were obesity and soft-tissue repair. Outside of Europe, Japan had the most non-US approvals in the quarter with five.

Approvals Clinical Trials
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Corindus Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Siemens Healthineers AG
  • Senior Management
  • Mark J Toland, Pres. & CEO
    David W Long, SVP, CFO
    Bryan McDonough, VP, US Sales
    Doug Teany, COO
  • Contact Info
  • Corindus Vascular Robotics Inc.
    Phone: (508) 653-3335
    309 Waverley Oaks Rd., Ste. 105
    Waltham, MA 02452
    USA
UsernamePublicRestriction

Register